Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting

No dose-limiting toxicities were observed, and a maximum tolerated dose was not determined

Data indicated an objective response rate of 25% in patients with desmoid tumors at the recommended Phase 2 dose

HOUSTON , June 1, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that results from a Phase 1 study of tegavivint in patients with desmoid tumors will be featured in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022). ASCO 2022 is being held June 3-7, 2022, in Chicago, Illinois.

Tegavivint is a potent and selective first-in-class small molecule inhibitor of Transducin Beta-like Protein One (TBL1), a novel downstream co-factor in the Wnt/beta-catenin signaling pathway.  Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types. Tegavivint's targeting of TBL1 prevents TBL1/beta-catenin complex formation, specifically inhibiting beta-catenin's oncogenic transcriptional activity without disrupting key cell membrane functions that have been linked to toxicity common to other drugs in this pathway.

The poster, titled, "Results of a phase I dose escalation study of a tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumors," will be presented on Sunday, June 5, 2022, at 11:30 a.m., CDT, during the Sarcoma session (poster number 428; abstract number 11523) by Lee D. Cranmer, M.D., Ph.D., F.A.C.P., principal investigator of the trial. The poster details results from the Phase 1 trial in adult patients with progressive, unresectable desmoid tumors. The primary objectives of the study were to evaluate safety and to determine the maximum tolerated dose (MTD),  the recommended Phase 2 dose (RP2D), and exploratory efficacy. No dose-limiting toxicities were observed and a maximum tolerated dose (MTD) was not determined. Treatment related adverse events were mostly Grade 1-2 with none resulting in treatment discontinuation. The RP2D was declared at 5 mg/kg based on pharmacologically relevant plasma concentrations and preliminary efficacy.  Responses were observed at all dose levels with an overall response rate of 25% at the RP2D.  Additionally, the 9 month progression free survival rate was 79% among those treated at the RP2D. Overall, these data demonstrated that tegavivint is well tolerated, does not appear to have the toxicity historically associated with WNT inhibition, and has promising clinical activity.

"The data presented at ASCO complements research presented earlier this year at AACR, which cumulatively demonstrate the safety, tolerability and clinical activity of tegavivint in the treatment of desmoid tumors," said Rahul Aras, PhD, CEO of Iterion. "We are particularly excited to present these results at ASCO, the world's preeminent oncology conference, because the data also serve to highlight the potential of our ongoing tegavivint programs in AML, non-small cell lung cancer, and pediatric solid tumors.  These cancer indications, like desmoid tumors, are associated with nuclear beta-catenin overexpression, which has historically been considered undruggable. We believe tegavivint's unique mechanism of action provides an opportunity to selectively disrupt the interaction of beta-catenin and TBL1, which in turn, allows for the specific degradation of nuclear beta-catenin without impacting key cell membrane functions that have been linked to previously reported toxicity."

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, tegavivint, is a potent and selective small molecule that binds to TBL1 in the nucleus, inhibiting nuclear beta-catenin signaling and oncogenic activity. Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that tegavivint has the potential for clinical utility in multiple cancer types. Currently, tegavivint is the subject of three separate clinical trials: a Phase 1 clinical trial sponsored by MD Anderson Cancer Center in patients with relapsed or refractory acute myeloid leukemia (AML); a Phase 1/2 clinical trial sponsored by Children's Oncology Group Pediatric Early Phase Clinical Trials Network in pediatric patients with sarcomas, lymphomas and other solid tumors, and a Phase 1 clinical trial sponsored by Ohio State University Comprehensive Cancer Center in EGRF-positive non-small cell lung cancer (NSCLC). Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on Iterion, please visit https://iteriontherapeutics.com.

Contact 
Tiberend Strategic Advisors, Inc.
Jason Rando (Media)
917-930-6346
[email protected]

SOURCE Iterion Therapeutics